Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Chronic myeloproliferative disorder

Known as: Myeloproliferative Disorder, MPD, Myeloproliferative Neoplasm 
A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic… Expand
National Institutes of Health

Related topics

Related topics

14 relations
Bone MarrowBone marrow stem cellEPSTI1 geneEPSTI1 wt Allele
Expand

Broader (1)

Myeloproliferative disease

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
New mutations and pathogenesis of myeloproliferative neoplasms.
Myeloproliferative neoplasms (MPNs) are clonal disorders characterized by excessive production of mature blood cells. In the… Expand
  • table 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
BACKGROUND Myelofibrosis is a Philadelphia chromosome–negative myeloproliferative neoplasm associated with cytopenias… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2010
Review
2010
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
Myeloproliferative neoplasms (MPNs) originate from genetically transformed hematopoietic stem cells that retain the capacity for… Expand
  • figure 1
  • table 1
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Disease alleles that activate signal transduction are common in myeloid malignancies; however, there are additional unidentified… Expand
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
Reporting of myelodysplastic syndromes (MDSs) and chronic myeloproliferative disorders (CMDs) to population-based cancer… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Background The JAK2V617F allele has recently been identified in patients with polycythemia vera (PV), essential thrombocytosis… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention
Haematopoietic stem cells (HSCs) must achieve a balance between quiescence and activation that fulfils immediate demands for… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
The analysis of rare chromosomal translocations in myeloproliferative disorders has highlighted the importance of aberrant… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
JunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells
The AP-1 transcription factor JunB is a transcriptional regulator of myelopoiesis. Inactivation of JunB in postnatal mice results… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE